These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 17404367

  • 1. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.
    Jatoi I, Chen BE, Anderson WF, Rosenberg PS.
    J Clin Oncol; 2007 May 01; 25(13):1683-90. PubMed ID: 17404367
    [Abstract] [Full Text] [Related]

  • 2. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
    Anderson WF, Chen BE, Jatoi I, Rosenberg PS.
    Breast Cancer Res Treat; 2006 Nov 01; 100(1):121-6. PubMed ID: 16685588
    [Abstract] [Full Text] [Related]

  • 3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Nov 01; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 4. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
    Yu KD, Wu J, Shen ZZ, Shao ZM.
    J Clin Endocrinol Metab; 2012 Dec 01; 97(12):E2201-9. PubMed ID: 22993034
    [Abstract] [Full Text] [Related]

  • 5. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer.
    Shen X, Anne PR, Keith SW, Wojcieszynski A, Mishra MV, Bar-Ad V, Showalter TN.
    Am J Clin Oncol; 2014 Jun 01; 37(3):241-7. PubMed ID: 23241502
    [Abstract] [Full Text] [Related]

  • 6. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
    Jemal A, Ward E, Thun MJ.
    Breast Cancer Res; 2007 Jun 01; 9(3):R28. PubMed ID: 17477859
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
    Sopik V, Sun P, Narod SA.
    Breast Cancer Res Treat; 2017 Sep 01; 165(2):391-402. PubMed ID: 28601929
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T3N0 invasive breast cancer? A SEER database analysis: outcomes by receptor status/race/age: analysis using the NCI Surveillance, Epidemiology, and End Results (SEER) database.
    Yan W, Christos P, Nori D, Chao KS, Ravi A.
    Am J Clin Oncol; 2013 Dec 01; 36(6):552-7. PubMed ID: 22868241
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
    Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K.
    Ann Surg Oncol; 2014 Oct 01; 21(10):3231-9. PubMed ID: 25081341
    [Abstract] [Full Text] [Related]

  • 14. Body weight correlates with mortality in early-stage breast cancer.
    Enger SM, Greif JM, Polikoff J, Press M.
    Arch Surg; 2004 Sep 01; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
    [Abstract] [Full Text] [Related]

  • 15. Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
    Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS.
    J Clin Oncol; 2006 Jun 20; 24(18):2750-6. PubMed ID: 16782915
    [Abstract] [Full Text] [Related]

  • 16. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
    Anderson WF, Jatoi I, Devesa SS.
    Breast Cancer Res Treat; 2005 Mar 20; 90(2):127-37. PubMed ID: 15803359
    [Abstract] [Full Text] [Related]

  • 17. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
    Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R.
    J Clin Oncol; 2006 Feb 20; 24(6):872-7. PubMed ID: 16484696
    [Abstract] [Full Text] [Related]

  • 18. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.
    Menashe I, Anderson WF, Jatoi I, Rosenberg PS.
    J Natl Cancer Inst; 2009 Jul 15; 101(14):993-1000. PubMed ID: 19584327
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.
    Jayasekara H, MacInnis RJ, Chamberlain JA, Dite GS, Leoce NM, Dowty JG, Bickerstaffe A, Win AK, Milne RL, Giles GG, Terry MB, Eccles DM, Southey MC, Hopper JL.
    Int J Cancer; 2019 Dec 15; 145(12):3207-3217. PubMed ID: 30771221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.